Farallon Capital Management's Schedule 13G Filing for Crinetics Pharmaceuticals, Inc.

Farallon Capital Management, L.L.C. and its affiliated entities have filed a Schedule 13G with the SEC, disclosing their beneficial ownership of shares in Crinetics Pharmaceuticals, Inc. The filing includes multiple Farallon funds and individual reporting persons, who collectively own a significant percentage of the company's common stock. The filing is made pursuant to Rule 13d-1(c) and indicates that the shares were not acquired for the purpose of influencing control of the issuer. The reporting persons have disclaimed beneficial ownership of the shares except to the extent of their pecuniary interest. The filing also includes a joint acquisition statement acknowledging the collective responsibility for the accuracy and completeness of the information provided.